Application
SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:
- to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
- to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
- to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)
Biochem/physiol Actions
SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.
Vanilloid receptor-1 (TRPV1) antagonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
- UPC:
- 10161533
- Condition:
- New
- HazmatClass:
- No
- MPN:
- S0441-25MG
- CAS:
- 472981-92-3
akash.verma@cenmed.com
(732) 447-1115





